Related Experiment Video For deficient mismatch repair
Updated: Apr 11, 2026

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma:
Chaoxian Xiong1, Weimin Wang1, Xuefeng Cha1
1Department of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Abstract:
Primary colon squamous cell carcinoma (SCC) is an extremely rare malignancy and associated with a poor prognosis. This case report describes a patient with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) ascending colon SCC, who was treated at our institution. After receiving four cycles of programmed cell death -1 (PD-1) blockade monotherapy, the tumor exhibited significant regression, and pathological complete response (pCR) was achieved following surgical resection. This case demonstrates that Anti-PD-1 therapy can induce clinically meaningful tumor regression even in this rare colon SCC subtype, suggesting a potential treatment strategy for dMMR/MSI-H colon SCC. These findings may provide valuable insights for clinicians managing similar cases. However, the feasibility and safety of immunotherapy in dMMR/MSI-H primary colon SCC require further validation through additional clinical studies.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017